Advertisement

Comparison of Site-Reported and Core Laboratory-Reported Creatine Kinase-MB Values in Non–ST-Segment Elevation Acute Coronary Syndrome (from the International Trial SYNERGY)

Published:September 28, 2009DOI:https://doi.org/10.1016/j.amjcard.2009.06.056
      The effect of nonstandardized creatine kinase (CK)-MB assays on the assessment of myocardial infarction (MI) end points in multicenter international trials has not been evaluated. We compared the site-reported and corresponding core laboratory CK-MB measures from 5 countries participating in the Superior Yield of the New Strategy of Enoxaparin, Revascularization, and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Samples for CK-MB were collected locally, with corresponding samples sent to a core laboratory at enrollment and after recurrent ischemic events, percutaneous coronary intervention, or coronary artery bypass grafting. The measured values were compared to the reported assay upper limits of normal (ULN) used at the site (or core laboratory for the core laboratory samples). The CK-MB results were available locally and from the core laboratory for 913 patients, constituting 4,693 time-matched laboratory values. The agreement between the core and site laboratory CK-MB/ULN ratio was moderate (concordance correlation coefficient 0.45) and varied considerably by geographic location and site. The CK-MB values were elevated (≥2 times the ULN) by the core laboratory but normal (<2 times the ULN) by local standards in 708 instances (15%). There were 162 MI end points according to the core laboratory values versus 91 MI end points using the site-reported CK-MB data (kappa statistic 0.48). Compared with patients with no MI by the core or site laboratory values, patients with MI, as determined by both the core and the site laboratories, had significantly lower unadjusted 1-year survival rates (80.6% vs 93.5%, p <0.0001). Patients with MI, as determined by the core laboratory but not by the site laboratory, showed a trend toward a lower 1-year survival rate (89.8% vs 93.5%, p = 0.20). In conclusion, a substantial variation in CK-MB ratios and MI outcomes between the site and core laboratory data was observed in the SYNERGY trial. More MI outcomes were identified by the core laboratory, and patients with MI as defined by core laboratory data had lower 1-year survival, making these events potentially clinically important.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Alpert J.S.
        • Thygesen K.
        • Antman E.
        • Bassand J.P.
        Myocardial infarction redefined—a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infraction.
        J Am Coll Cardiol. 2000; 36: 959-969
        • SYNERGY Executive Committee
        The SYNERGY trial: study design and rationale.
        Am Heart J. 2002; 143: 952-960
        • The SYNERGY Trial Investigators
        Enoxaparin vs unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
        JAMA. 2004; 292: 45-54
        • Lin L.I.
        A concordance correlation coefficient to evaluate reproducibility.
        Biometrics. 1989; 45: 255-268
        • Lin L.I.
        A note on the concordance correlation coefficient.
        Biometrics. 2000; 56: 324-325
        • Wu A.H.B.
        • Apple F.S.
        • Gibler W.B.
        • Jesse R.L.
        • Warshaw M.M.
        • Valdes Jr, R.
        National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendation for the use of cardiac marker in coronary artery diseases.
        Clin Chem. 1999; 45: 1104-1121
      1. The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators.
        N Engl J Med. 1999; 339: 436-443
        • Christenson R.H.
        • Vaidya H.
        • Landt Y.
        • Bauer R.S.
        • Green S.F.
        • Apple F.A.
        • Jacob A.
        • Magneson G.R.
        • Nag S.
        • Wu A.H.
        • Azzazy H.M.
        Standardization of creatine kinase-MB (CK-MB) mass assays: the use of recombinant CK-MB as a reference material.
        Clin Chem. 1999; 45: 1414-1423
        • Panteghini M.
        • Pagani F.
        AACC creatine kinase MB (CK-MB) standardization material used as manufacturer's working calibrator is unable to harmonize CK-MB results between 2 commercial immunoassays.
        Clin Chem. 2004; 50: 1711-1712
        • Apple F.S.
        Clinical and analytical issues confronting cardiac troponin I.
        Clin Chem. 1999; 45: 18-20
        • Panteghini M.
        • Bunk D.M.
        • Christenson R.H.
        • Katrukha A.
        • Porter R.A.
        • Schimmel H.
        • Wang L.
        • Tate J.R.
        • IFCC Working Group on Standardization of Troponin
        I. Standardization of troponin I measurements: an update.
        Clin Chem Lab Med. 2008; 46: 1501-1506
        • Akkerhuis K.M.
        • Deckers J.W.
        • Boersma E.
        • Harrington R.A.
        • Stepinska J.
        • Mahaffey K.W.
        • Wilcox R.G.
        • Lincoff A.M.
        • Keltai M.
        • Topol E.J.
        • Califf R.M.
        • Simoons M.L.
        Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes.
        Eur Heart J. 2000; 21: 371-381
        • Apple F.S.
        • Murakami M.
        • Panteghini M.
        • Christenson R.H.
        • Dati F.
        • Mair J.
        • Wu A.H.
        • I.F.C.C. Committee on Standardization of Markers of Cardiac Damage
        International survey on the use of cardiac markers.
        Clin Chem. 2001; 47: 587-588
        • Lagakos S.W.
        The challenge of subgroup analyses: reporting without distorting.
        N Engl J Med. 2006; 354: 1667-1669
        • Apple F.S.
        • Jesse R.L.
        • Newby K.
        • Wu A.H.B.
        • Christenson R.H.
        National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage laboratory medicine practice guidelines: analytical issues for biochemical markers of acute coronary syndromes.
        Circulation. 2007; 115: e342-e355
        • Apple F.S.
        • Quist H.E.
        • Doyle P.J.
        • Otto A.P.
        • Murakami M.M.
        Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations.
        Clin Chem. 2003; 49: 1331-1336
        • Guo Z.
        • Wang Z.
        • Wang X.
        Studies on the stability of creatine kinase isozymes.
        Biochem Cell Biol. 2003; 81: 9-16
        • Buttery J.E.
        • Stuart S.
        • Pannall P.R.
        Stability of the CK-MB isoenzyme on routine storage.
        Clin Biochem. 1992; 25: 11-13